nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.15	0.295	CbGbCtD
Agomelatine—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.126	0.247	CbGbCtD
Agomelatine—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.12	0.236	CbGbCtD
Agomelatine—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0586	0.115	CbGbCtD
Agomelatine—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0538	0.106	CbGbCtD
Agomelatine—Paraesthesia—Topotecan—peripheral nervous system neoplasm	0.00138	0.00291	CcSEcCtD
Agomelatine—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.00138	0.00291	CcSEcCtD
Agomelatine—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.00138	0.00291	CcSEcCtD
Agomelatine—Jaundice—Etoposide—peripheral nervous system neoplasm	0.00138	0.00291	CcSEcCtD
Agomelatine—Mental disorder—Vincristine—peripheral nervous system neoplasm	0.00138	0.0029	CcSEcCtD
Agomelatine—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.00137	0.00289	CcSEcCtD
Agomelatine—Paraesthesia—Isotretinoin—peripheral nervous system neoplasm	0.00137	0.00289	CcSEcCtD
Agomelatine—Paraesthesia—Tretinoin—peripheral nervous system neoplasm	0.00137	0.00289	CcSEcCtD
Agomelatine—Connective tissue disorder—Cisplatin—peripheral nervous system neoplasm	0.00136	0.00287	CcSEcCtD
Agomelatine—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.00136	0.00286	CcSEcCtD
Agomelatine—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.00136	0.00286	CcSEcCtD
Agomelatine—Dyspepsia—Topotecan—peripheral nervous system neoplasm	0.00136	0.00286	CcSEcCtD
Agomelatine—Paraesthesia—Melphalan—peripheral nervous system neoplasm	0.00135	0.00285	CcSEcCtD
Agomelatine—Dyspepsia—Tretinoin—peripheral nervous system neoplasm	0.00134	0.00283	CcSEcCtD
Agomelatine—Dyspepsia—Isotretinoin—peripheral nervous system neoplasm	0.00134	0.00283	CcSEcCtD
Agomelatine—Hepatobiliary disease—Etoposide—peripheral nervous system neoplasm	0.00134	0.00282	CcSEcCtD
Agomelatine—Vision blurred—Alitretinoin—peripheral nervous system neoplasm	0.00134	0.00282	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.00133	0.0028	CcSEcCtD
Agomelatine—Tremor—Alitretinoin—peripheral nervous system neoplasm	0.00133	0.0028	CcSEcCtD
Agomelatine—Fatigue—Topotecan—peripheral nervous system neoplasm	0.00133	0.0028	CcSEcCtD
Agomelatine—Dyspepsia—Melphalan—peripheral nervous system neoplasm	0.00133	0.0028	CcSEcCtD
Agomelatine—Back pain—Vincristine—peripheral nervous system neoplasm	0.00132	0.00279	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.00132	0.00278	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.00132	0.00278	CcSEcCtD
Agomelatine—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.00132	0.00277	CcSEcCtD
Agomelatine—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.00132	0.00277	CcSEcCtD
Agomelatine—Constipation—Topotecan—peripheral nervous system neoplasm	0.00132	0.00277	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—peripheral nervous system neoplasm	0.00131	0.00277	CcSEcCtD
Agomelatine—Constipation—Tretinoin—peripheral nervous system neoplasm	0.00131	0.00275	CcSEcCtD
Agomelatine—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.00131	0.00275	CcSEcCtD
Agomelatine—Agitation—Alitretinoin—peripheral nervous system neoplasm	0.0013	0.00275	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.0013	0.00274	CcSEcCtD
Agomelatine—Fatigue—Melphalan—peripheral nervous system neoplasm	0.0013	0.00274	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—peripheral nervous system neoplasm	0.0013	0.00274	CcSEcCtD
Agomelatine—Eye disorder—Cisplatin—peripheral nervous system neoplasm	0.0013	0.00273	CcSEcCtD
Agomelatine—Tinnitus—Cisplatin—peripheral nervous system neoplasm	0.00129	0.00273	CcSEcCtD
Agomelatine—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.00126	0.00265	CcSEcCtD
Agomelatine—Agitation—Vincristine—peripheral nervous system neoplasm	0.00126	0.00265	CcSEcCtD
Agomelatine—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00125	0.00263	CcSEcCtD
Agomelatine—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00125	0.00263	CcSEcCtD
Agomelatine—Infection—Dactinomycin—peripheral nervous system neoplasm	0.00124	0.00261	CcSEcCtD
Agomelatine—Vertigo—Vincristine—peripheral nervous system neoplasm	0.00123	0.00259	CcSEcCtD
Agomelatine—Urticaria—Topotecan—peripheral nervous system neoplasm	0.00122	0.00258	CcSEcCtD
Agomelatine—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00122	0.00256	CcSEcCtD
Agomelatine—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.00121	0.00256	CcSEcCtD
Agomelatine—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.00121	0.00256	CcSEcCtD
Agomelatine—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00121	0.00254	CcSEcCtD
Agomelatine—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00121	0.00254	CcSEcCtD
Agomelatine—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.0012	0.00254	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.0012	0.00253	CcSEcCtD
Agomelatine—Urticaria—Melphalan—peripheral nervous system neoplasm	0.0012	0.00252	CcSEcCtD
Agomelatine—Eye disorder—Etoposide—peripheral nervous system neoplasm	0.00119	0.0025	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Epirubicin—peripheral nervous system neoplasm	0.00118	0.0025	CcSEcCtD
Agomelatine—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.00118	0.00249	CcSEcCtD
Agomelatine—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00115	0.00242	CcSEcCtD
Agomelatine—Eczema—Epirubicin—peripheral nervous system neoplasm	0.00115	0.00242	CcSEcCtD
Agomelatine—Hepatic failure—Epirubicin—peripheral nervous system neoplasm	0.00115	0.00242	CcSEcCtD
Agomelatine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.00114	0.0024	CcSEcCtD
Agomelatine—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00114	0.00239	CcSEcCtD
Agomelatine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.00113	0.00239	CcSEcCtD
Agomelatine—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.00112	0.00237	CcSEcCtD
Agomelatine—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.00112	0.00236	CcSEcCtD
Agomelatine—Infection—Vincristine—peripheral nervous system neoplasm	0.00111	0.00233	CcSEcCtD
Agomelatine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.0011	0.00233	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—peripheral nervous system neoplasm	0.0011	0.00231	CcSEcCtD
Agomelatine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.0011	0.00231	CcSEcCtD
Agomelatine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.0011	0.00231	CcSEcCtD
Agomelatine—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.00109	0.0023	CcSEcCtD
Agomelatine—Pruritus—Topotecan—peripheral nervous system neoplasm	0.00109	0.0023	CcSEcCtD
Agomelatine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00108	0.00228	CcSEcCtD
Agomelatine—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00108	0.00228	CcSEcCtD
Agomelatine—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00108	0.00228	CcSEcCtD
Agomelatine—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.00108	0.00227	CcSEcCtD
Agomelatine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00108	0.00227	CcSEcCtD
Agomelatine—Back pain—Etoposide—peripheral nervous system neoplasm	0.00107	0.00226	CcSEcCtD
Agomelatine—Pruritus—Melphalan—peripheral nervous system neoplasm	0.00107	0.00225	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—peripheral nervous system neoplasm	0.00106	0.00224	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—peripheral nervous system neoplasm	0.00106	0.00224	CcSEcCtD
Agomelatine—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00105	0.00222	CcSEcCtD
Agomelatine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.00105	0.00221	CcSEcCtD
Agomelatine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00105	0.0022	CcSEcCtD
Agomelatine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00105	0.0022	CcSEcCtD
Agomelatine—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.00104	0.00219	CcSEcCtD
Agomelatine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00103	0.00217	CcSEcCtD
Agomelatine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.00103	0.00217	CcSEcCtD
Agomelatine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.00103	0.00216	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00102	0.00215	CcSEcCtD
Agomelatine—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00102	0.00215	CcSEcCtD
Agomelatine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.00102	0.00215	CcSEcCtD
Agomelatine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00102	0.00215	CcSEcCtD
Agomelatine—Migraine—Epirubicin—peripheral nervous system neoplasm	0.00101	0.00214	CcSEcCtD
Agomelatine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00101	0.00213	CcSEcCtD
Agomelatine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00101	0.00213	CcSEcCtD
Agomelatine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00101	0.00213	CcSEcCtD
Agomelatine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.001	0.00211	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000999	0.00211	CcSEcCtD
Agomelatine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000998	0.0021	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—peripheral nervous system neoplasm	0.000995	0.0021	CcSEcCtD
Agomelatine—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000995	0.0021	CcSEcCtD
Agomelatine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00099	0.00209	CcSEcCtD
Agomelatine—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000987	0.00208	CcSEcCtD
Agomelatine—Infection—Cisplatin—peripheral nervous system neoplasm	0.00098	0.00206	CcSEcCtD
Agomelatine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000979	0.00206	CcSEcCtD
Agomelatine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000971	0.00205	CcSEcCtD
Agomelatine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000971	0.00205	CcSEcCtD
Agomelatine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000967	0.00204	CcSEcCtD
Agomelatine—Headache—Topotecan—peripheral nervous system neoplasm	0.000965	0.00203	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000963	0.00203	CcSEcCtD
Agomelatine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000962	0.00203	CcSEcCtD
Agomelatine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000959	0.00202	CcSEcCtD
Agomelatine—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000958	0.00202	CcSEcCtD
Agomelatine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000957	0.00202	CcSEcCtD
Agomelatine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000957	0.00202	CcSEcCtD
Agomelatine—Constipation—Vincristine—peripheral nervous system neoplasm	0.000954	0.00201	CcSEcCtD
Agomelatine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000953	0.00201	CcSEcCtD
Agomelatine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000947	0.00199	CcSEcCtD
Agomelatine—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000939	0.00198	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000936	0.00197	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000922	0.00194	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000921	0.00194	CcSEcCtD
Agomelatine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00092	0.00194	CcSEcCtD
Agomelatine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000915	0.00193	CcSEcCtD
Agomelatine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000915	0.00193	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000912	0.00192	CcSEcCtD
Agomelatine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000907	0.00191	CcSEcCtD
Agomelatine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000907	0.00191	CcSEcCtD
Agomelatine—Infection—Etoposide—peripheral nervous system neoplasm	0.000898	0.00189	CcSEcCtD
Agomelatine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000896	0.00189	CcSEcCtD
Agomelatine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000896	0.00189	CcSEcCtD
Agomelatine—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000891	0.00188	CcSEcCtD
Agomelatine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000886	0.00187	CcSEcCtD
Agomelatine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000882	0.00186	CcSEcCtD
Agomelatine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000878	0.00185	CcSEcCtD
Agomelatine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000874	0.00184	CcSEcCtD
Agomelatine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000854	0.0018	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000853	0.0018	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000852	0.00179	CcSEcCtD
Agomelatine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000831	0.00175	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000824	0.00174	CcSEcCtD
Agomelatine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000819	0.00173	CcSEcCtD
Agomelatine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000811	0.00171	CcSEcCtD
Agomelatine—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000811	0.00171	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000806	0.0017	CcSEcCtD
Agomelatine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000803	0.00169	CcSEcCtD
Agomelatine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.0008	0.00169	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000794	0.00167	CcSEcCtD
Agomelatine—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000794	0.00167	CcSEcCtD
Agomelatine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000794	0.00167	CcSEcCtD
Agomelatine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000792	0.00167	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00078	0.00164	CcSEcCtD
Agomelatine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000779	0.00164	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000774	0.00163	CcSEcCtD
Agomelatine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000773	0.00163	CcSEcCtD
Agomelatine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000765	0.00161	CcSEcCtD
Agomelatine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000763	0.00161	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000751	0.00158	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.00075	0.00158	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000746	0.00157	CcSEcCtD
Agomelatine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000742	0.00156	CcSEcCtD
Agomelatine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000739	0.00156	CcSEcCtD
Agomelatine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000738	0.00155	CcSEcCtD
Agomelatine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000736	0.00155	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000735	0.00155	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000735	0.00155	CcSEcCtD
Agomelatine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000725	0.00153	CcSEcCtD
Agomelatine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000718	0.00151	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000716	0.00151	CcSEcCtD
Agomelatine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000714	0.00151	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000713	0.0015	CcSEcCtD
Agomelatine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000709	0.00149	CcSEcCtD
Agomelatine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000708	0.00149	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000701	0.00148	CcSEcCtD
Agomelatine—Headache—Vincristine—peripheral nervous system neoplasm	0.000699	0.00147	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000695	0.00146	CcSEcCtD
Agomelatine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000688	0.00145	CcSEcCtD
Agomelatine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000675	0.00142	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000666	0.0014	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000665	0.0014	CcSEcCtD
Agomelatine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000663	0.0014	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.00066	0.00139	CcSEcCtD
Agomelatine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000648	0.00137	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000648	0.00137	CcSEcCtD
Agomelatine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000639	0.00135	CcSEcCtD
Agomelatine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000627	0.00132	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000625	0.00132	CcSEcCtD
Agomelatine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000618	0.0013	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000616	0.0013	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000615	0.0013	CcSEcCtD
Agomelatine—Back pain—Epirubicin—peripheral nervous system neoplasm	0.0006	0.00126	CcSEcCtD
Agomelatine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000598	0.00126	CcSEcCtD
Agomelatine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000586	0.00123	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000585	0.00123	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000578	0.00122	CcSEcCtD
Agomelatine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000575	0.00121	CcSEcCtD
Agomelatine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.00057	0.0012	CcSEcCtD
Agomelatine—Headache—Etoposide—peripheral nervous system neoplasm	0.000566	0.00119	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000558	0.00117	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000555	0.00117	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000541	0.00114	CcSEcCtD
Agomelatine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000537	0.00113	CcSEcCtD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000532	0.0303	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000532	0.0303	CbGpPWpGaD
Agomelatine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000528	0.00111	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000527	0.00111	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000525	0.00111	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000517	0.00109	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000516	0.00109	CcSEcCtD
Agomelatine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000503	0.00106	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000497	0.00105	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000492	0.00104	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00049	0.00103	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000487	0.00103	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000486	0.00102	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000478	0.00101	CcSEcCtD
Agomelatine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000466	0.000981	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00046	0.000968	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000458	0.000965	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000455	0.000959	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000455	0.000958	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000453	0.000955	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.00045	0.000949	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000446	0.000939	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000437	0.000921	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000437	0.00092	CcSEcCtD
Agomelatine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000433	0.000913	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000424	0.000893	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000421	0.000887	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000417	0.000878	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000414	0.000873	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000413	0.000869	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000405	0.0231	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000405	0.0231	CbGpPWpGaD
Agomelatine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000405	0.000853	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.000851	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000402	0.000848	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000401	0.000844	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.0004	0.000844	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000388	0.0221	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000388	0.0221	CbGpPWpGaD
Agomelatine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000383	0.000808	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000372	0.000784	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.00037	0.000781	CcSEcCtD
Agomelatine—MTNR1A—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000365	0.0208	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000365	0.0208	CbGpPWpGaD
Agomelatine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000363	0.000766	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000358	0.000755	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000347	0.00073	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000336	0.000709	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000335	0.000706	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000332	0.000699	CcSEcCtD
Agomelatine—MTNR1B—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000325	0.0185	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000325	0.0185	CbGpPWpGaD
Agomelatine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000679	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000321	0.000676	CcSEcCtD
Agomelatine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000317	0.000669	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.00031	0.000653	CcSEcCtD
Agomelatine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000301	0.000634	CcSEcCtD
Agomelatine—MTNR1B—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000301	0.0171	CbGpPWpGaD
Agomelatine—MTNR1A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000301	0.0171	CbGpPWpGaD
Agomelatine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000628	CcSEcCtD
Agomelatine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.000619	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000587	CcSEcCtD
Agomelatine—MTNR1A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000263	0.015	CbGpPWpGaD
Agomelatine—MTNR1B—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000263	0.015	CbGpPWpGaD
Agomelatine—HTR2B—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000259	0.0148	CbGpPWpGaD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—peripheral nervous system neoplasm	0.000255	0.0145	CbGpPWpGaD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000239	0.0136	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000239	0.0136	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000232	0.0132	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000229	0.013	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000229	0.013	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000209	0.0119	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000208	0.0118	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000208	0.0118	CbGpPWpGaD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—peripheral nervous system neoplasm	0.000205	0.0117	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000204	0.0116	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000199	0.0114	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000199	0.0114	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000187	0.0107	CbGpPWpGaD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—peripheral nervous system neoplasm	0.000186	0.0106	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000182	0.0104	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000182	0.0104	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000174	0.00989	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000174	0.00989	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000172	0.00979	CbGpPWpGaD
Agomelatine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000169	0.00963	CbGpPWpGaD
Agomelatine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000161	0.00917	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000159	0.00907	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000159	0.00907	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000158	0.00898	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000158	0.00898	CbGpPWpGaD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—peripheral nervous system neoplasm	0.00015	0.00856	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000145	0.00829	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000145	0.00829	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000139	0.0079	CbGpPWpGaD
Agomelatine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000138	0.00784	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000131	0.00745	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000125	0.00714	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000123	0.007	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000123	0.007	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000118	0.00671	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000118	0.00671	CbGpPWpGaD
Agomelatine—HTR2B—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000117	0.00664	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000106	0.00601	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000104	0.00594	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000103	0.00586	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000103	0.00586	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000101	0.00576	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	9.52e-05	0.00543	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	9.52e-05	0.00543	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	9.4e-05	0.00536	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.34e-05	0.00532	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.34e-05	0.00532	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.31e-05	0.0053	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.31e-05	0.0053	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9e-05	0.00513	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9e-05	0.00513	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	8.59e-05	0.00489	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	8.59e-05	0.00489	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	8.41e-05	0.00479	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.17e-05	0.00466	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.17e-05	0.00466	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	7.72e-05	0.0044	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	7.39e-05	0.00421	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	6.71e-05	0.00382	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.45e-05	0.00368	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.45e-05	0.00368	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	6.43e-05	0.00367	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	6.33e-05	0.00361	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	6.23e-05	0.00355	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	6.06e-05	0.00346	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.96e-05	0.0034	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	5.88e-05	0.00335	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.68e-05	0.00323	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.68e-05	0.00323	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	5.6e-05	0.00319	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.52e-05	0.00314	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.52e-05	0.00314	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.41e-05	0.00309	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.26e-05	0.003	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.26e-05	0.003	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	5.19e-05	0.00296	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.18e-05	0.00295	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	5.14e-05	0.00293	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	5.11e-05	0.00291	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	5.09e-05	0.0029	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.83e-05	0.00275	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.83e-05	0.00275	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.74e-05	0.0027	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	4.69e-05	0.00267	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	4.6e-05	0.00262	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.52e-05	0.00258	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	4.28e-05	0.00244	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	4.15e-05	0.00236	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	4.1e-05	0.00234	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4e-05	0.00228	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.96e-05	0.00226	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	3.81e-05	0.00217	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.8e-05	0.00217	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.79e-05	0.00216	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.42e-05	0.00195	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.41e-05	0.00195	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.41e-05	0.00195	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	3.37e-05	0.00192	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.35e-05	0.00191	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.35e-05	0.00191	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.32e-05	0.00189	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.2e-05	0.00182	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	3.07e-05	0.00175	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.07e-05	0.00175	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.02e-05	0.00172	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VIP—peripheral nervous system neoplasm	3e-05	0.00171	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.9e-05	0.00165	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.79e-05	0.00159	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.77e-05	0.00158	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.7e-05	0.00154	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.68e-05	0.00153	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.65e-05	0.00151	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.65e-05	0.00151	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.64e-05	0.0015	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.5e-05	0.00142	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.5e-05	0.00142	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.43e-05	0.00139	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.43e-05	0.00138	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.43e-05	0.00138	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.42e-05	0.00138	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.41e-05	0.00137	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.41e-05	0.00137	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.34e-05	0.00134	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.31e-05	0.00131	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.25e-05	0.00128	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.24e-05	0.00128	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.24e-05	0.00127	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.2e-05	0.00126	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.2e-05	0.00126	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.13e-05	0.00121	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.08e-05	0.00119	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.02e-05	0.00115	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.02e-05	0.00115	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.95e-05	0.00111	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.92e-05	0.00109	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.88e-05	0.00107	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.88e-05	0.00107	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.87e-05	0.00107	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.83e-05	0.00104	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.8e-05	0.00103	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.78e-05	0.00102	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.7e-05	0.000967	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.68e-05	0.000957	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.67e-05	0.000951	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.6e-05	0.000911	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.56e-05	0.000888	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.54e-05	0.000879	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.54e-05	0.000879	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.54e-05	0.000877	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.48e-05	0.000843	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.48e-05	0.000841	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.48e-05	0.000841	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.44e-05	0.000819	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.37e-05	0.000781	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000742	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000742	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.26e-05	0.000716	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.18e-05	0.000674	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.1e-05	0.000628	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.08e-05	0.000617	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.01e-05	0.000576	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	9.99e-06	0.00057	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.53e-06	0.000543	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	9.4e-06	0.000535	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.89e-06	0.000507	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.73e-06	0.000498	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.56e-06	0.000488	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.54e-06	0.000487	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.15e-06	0.000464	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	8.06e-06	0.000459	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	8.03e-06	0.000458	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.84e-06	0.000447	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.77e-06	0.000443	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	7.67e-06	0.000437	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	7.53e-06	0.000429	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.12e-06	0.000406	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.9e-06	0.000393	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.55e-06	0.000374	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.51e-06	0.000371	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.5e-06	0.000371	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.43e-06	0.000367	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.32e-06	0.00036	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.27e-06	0.000357	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.06e-06	0.000346	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.74e-06	0.000327	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.25e-06	0.000299	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.98e-06	0.000284	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.89e-06	0.000279	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.76e-06	0.000271	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.2e-06	0.00024	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.02e-06	0.000229	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.84e-06	0.000219	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.39e-06	0.000193	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	2.07e-06	0.000118	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.77e-06	0.000101	CbGpPWpGaD
